Pharminent

FDA advisers back Grail’s multicancer detection blood test

An FDA advisory panel supported Grail’s multicancer detection blood test, described as the first of its kind. Panel members said the test should not be used to replace cancer screenings recommended by medical guidelines.

FDA grants priority review to AstraZeneca’s Imfinzi in bladder cancer

The FDA has begun an accelerated review of a new bladder cancer indication for AstraZeneca’s Imfinzi.

FDA nominee Overton parries vaccine questions at Senate hearing

At her Senate confirmation hearing Thursday, FDA commissioner nominee Heidi Overton said she would “follow the law” on key decisions and work to speed early drug research, while lawmakers pressed her on vaccines, the abortion pill and vapes. Overton affirmed the safety of the MMR vaccine, and senators questioned whether she would challenge statements from President Trump.

FDA approves Onswik for adults with type 2 diabetes

The FDA has approved Onswik for adults with type 2 diabetes.

Novo licenses Nanexa’s PharmaShell for long-acting injectables

Novo signed a $1.33 billion licensing agreement for global rights to use Nanexa’s PharmaShell drug-delivery technology, which coats drug particles to control their release, across up to five long-acting injectable programs in obesity, type 2 diabetes and other cardiometabolic disease. Nanexa’s shares rose more than 150% at the open in Stockholm before paring to about 114%.

Roche and Earendil sign $1.5B bispecific discovery deal

Roche and Earendil agreed to a bispecific oncology discovery and development deal valued at up to $1.5 billion, centered on Earendil’s AI-powered drug discovery platform. Sanofi has also partnered with Earendil on the platform.

Lilly pays InnoCare $100M to start R&D partnership

Eli Lilly is paying InnoCare Pharma $100 million upfront to begin a drug discovery and development partnership. Indications for the alliance were not disclosed; InnoCare specializes in oncology and autoimmune drugs.

Amberstone and Henlius partner on solid tumor T-cell engagers

Amberstone Biosciences signed a partnership and license agreement with Shanghai Henlius Biotech covering conditionally activated T-cell engager candidates for solid tumors.

ADARx raises $446M in RNAi biotech IPO

RNAi drug developer ADARx raised $446 million in its initial public offering. It is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price a US IPO in more than a decade.